ATE492564T1 - Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum - Google Patents

Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum

Info

Publication number
ATE492564T1
ATE492564T1 AT05730286T AT05730286T ATE492564T1 AT E492564 T1 ATE492564 T1 AT E492564T1 AT 05730286 T AT05730286 T AT 05730286T AT 05730286 T AT05730286 T AT 05730286T AT E492564 T1 ATE492564 T1 AT E492564T1
Authority
AT
Austria
Prior art keywords
ephb4
tumor growth
binding antibodies
inhibiting angiogenesis
present
Prior art date
Application number
AT05730286T
Other languages
English (en)
Inventor
Valery Krasnoperov
Sergey Zozulya
Nathalie Kertesz
Ramachandra Reddy
Parkash Gill
Original Assignee
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/800,350 external-priority patent/US7862816B2/en
Priority claimed from US10/949,720 external-priority patent/US7381410B2/en
Application filed by Vasgene Therapeutics Inc filed Critical Vasgene Therapeutics Inc
Priority claimed from PCT/US2005/008280 external-priority patent/WO2005090406A2/en
Application granted granted Critical
Publication of ATE492564T1 publication Critical patent/ATE492564T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05730286T 2004-03-12 2005-03-11 Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum ATE492564T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/800,350 US7862816B2 (en) 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth
US61290804P 2004-09-23 2004-09-23
US10/949,720 US7381410B2 (en) 2003-03-12 2004-09-23 Polypeptide compounds for inhibiting angiogenesis and tumor growth
PCT/US2005/008280 WO2005090406A2 (en) 2004-03-12 2005-03-11 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth

Publications (1)

Publication Number Publication Date
ATE492564T1 true ATE492564T1 (de) 2011-01-15

Family

ID=43402946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05730286T ATE492564T1 (de) 2004-03-12 2005-03-11 Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum

Country Status (7)

Country Link
US (1) US8981062B2 (de)
JP (1) JP2011168614A (de)
KR (2) KR20120123619A (de)
CN (2) CN102718867A (de)
AT (1) ATE492564T1 (de)
DE (1) DE602005025459D1 (de)
DK (1) DK1730196T3 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140057025A (ko) 2012-11-02 2014-05-12 현대자동차주식회사 Lpg 직접 분사 시스템
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN114409792B (zh) * 2021-12-01 2022-08-12 中山大学附属第五医院 抗EphB4纳米抗体

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
CA2111006C (en) 1991-06-21 2008-04-08 Andrew D. Boyd A novel receptor-type tyrosine kinase and use thereof
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
CA2128722A1 (en) 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
AU685765B2 (en) 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
US5512591A (en) 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
ES2152753B1 (es) 1993-03-29 2001-09-01 Ct Investig Energeticas Ciemat Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5624899A (en) 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
AU3144195A (en) 1994-07-26 1996-02-22 Rutgers, The State University Of New Jersey Human brain specific kinase
US5795734A (en) 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
WO1996013518A1 (en) 1994-10-27 1996-05-09 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
US5837534A (en) 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
AUPN727795A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel receptor-type tyrosine kinase and use thereof
US6696557B1 (en) 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5797954A (en) 1996-05-24 1998-08-25 Shaffer; Terry M. Accessing and deaccessing tools and methods
US6413730B1 (en) 1996-07-05 2002-07-02 Mount Sinai Hospital Corporation Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6440954B1 (en) 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
WO1999008696A1 (en) 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
EP1019080A2 (de) 1997-10-02 2000-07-19 Leukosite, Inc. Modulierung von durch lerk-2 vermittelten zelladhäsionen
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AU8788998A (en) 1998-10-02 2000-04-06 Universite Paris 7 Vascular specific regulatory elements contained in the desmin 5' flanking region
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
ATE293989T1 (de) 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
WO2001049743A2 (en) 2000-01-06 2001-07-12 The Hospital For Sick Children Methods of modulation of the immune system
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
JP2003530871A (ja) 2000-04-21 2003-10-21 アムジエン・インコーポレーテツド インテグリン／接着因子アンタゴニスト
WO2002011785A2 (en) 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
WO2002026827A1 (en) 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
CA2429460A1 (en) 2000-11-20 2002-05-23 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
US6958140B2 (en) 2001-01-26 2005-10-25 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
EP1358211A2 (de) 2001-01-31 2003-11-05 Mount Sinai Hospital Verfahren zur regulierung der ephb2 kinase domäne
WO2002063037A2 (en) 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
WO2002079382A2 (en) 2001-03-30 2002-10-10 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2452578A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
US20060241027A1 (en) 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
EP1575509B1 (de) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US20040110150A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
EP1606305A4 (de) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nukleinsäureverbindungen für die inhibierung von angiogenese und tumorwachstum
NZ543122A (en) 2003-03-24 2008-07-31 Sequoia Pharmaceuticals Inc An HIV fusion inhibitor peptide covalently linked to a blood protein
WO2004091375A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US20050049176A1 (en) 2003-04-11 2005-03-03 Kiener Peter A. EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
EP2441474B1 (de) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Verfahren und Zusammensetzungen zur Modulation der Adipozytfunktion
CN1905899B (zh) 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
EP2275445A3 (de) 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth

Also Published As

Publication number Publication date
CN102718867A (zh) 2012-10-10
HK1116198A1 (en) 2008-12-19
US20130344075A1 (en) 2013-12-26
DK1730196T3 (da) 2011-03-28
US8981062B2 (en) 2015-03-17
KR20070034465A (ko) 2007-03-28
CN102746401A (zh) 2012-10-24
KR20120123619A (ko) 2012-11-08
JP2011168614A (ja) 2011-09-01
HK1101695A1 (en) 2007-10-26
DE602005025459D1 (de) 2011-02-03

Similar Documents

Publication Publication Date Title
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
DK2269656T3 (da) Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
UA92504C2 (en) Anti-myostatin monoclonal antibody
DE602006013029D1 (de) Anti-egfr-antikörper
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
WO2006118772A3 (en) Fcrn antibodies and uses thereof
IL214325A (en) Antibody against cmet, a drug that includes and uses it
TW200639182A (en) Antibody variants and uses thereof
NO20083053L (no) Humane monoklonale antistoffer mot O8E
MX2010003380A (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
NZ599875A (en) Human il-23 antigen binding proteins
EP1844077A4 (de) Dr5-antikörper und deren verwendung
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
GB0324656D0 (en) A protein involved in ovarian cancer
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
TW200643031A (en) Pest control

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties